Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib

Metastatic breast cancer (mBC) patients have a high risk of progression and face poor prognosis overall, with about one third (34%) surviving five years or more. In rare instances (2–4% of cases) patients with mBC have ERBB2 (HER2) activating mutations but are ERBB2 non-amplified. Neratinib is a pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Shishido, Stephanie N., Masson, Rahul, Xu, Liya, Welter, Lisa, Prabakar, Rishvanth Kaliappan, D’ Souza, Anishka, Spicer, Darcy, Kang, Irene, Jayachandran, Priya, Hicks, James, Lu, Janice, Kuhn, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857263/
https://www.ncbi.nlm.nih.gov/pubmed/35181666
http://dx.doi.org/10.1038/s41523-022-00390-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857263/
https://www.ncbi.nlm.nih.gov/pubmed/35181666
http://dx.doi.org/10.1038/s41523-022-00390-5

Ejemplares similares